Related Experiment Video
Updated: Jul 18, 2026
10:10
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Inhibitory effect of Ginkgo biloba extract on human platelet aggregation
A K Dutta-Roy1, M J Gordon, C Kelly
1Rowett Research Institute, Greenburn Road, Bucksburn, Aberdeen AB21 9SB, Scotland, UK. adr@rri.sari.ac.uk
Platelets
|June 28, 2006
Summary
Ginkgo biloba extract (GBE) effectively inhibits human platelet aggregation in whole blood and plasma. This extract may serve as a potential oral anti-platelet therapeutic agent.
Area of Science:
- Pharmacology
- Biochemistry
- Cardiovascular Research
Background:
- Platelet aggregation plays a crucial role in thrombosis.
- Flavonoids and Ginkgo biloba extract (GBE) are investigated for their potential anti-platelet effects.
Purpose of the Study:
- To investigate the effects of pure flavonoids and GBE on human platelet aggregation.
- To elucidate the mechanisms underlying GBE's anti-platelet activity.
Main Methods:
- Platelet aggregation assays were performed using platelet-rich plasma (PRP), gel-filtered platelets (GFP), and whole blood.
- Effects on thromboxane A2 (TxA2) production, platelet membrane fluidity, and cyclic AMP (cAMP) levels were measured.
Main Results:
- GBE significantly inhibited ADP- and collagen-induced platelet aggregation in a dose-dependent manner across PRP, GFP, and whole blood.
- While GBE and some flavonoids reduced TxA2 production, no direct correlation with aggregation inhibition was found.
- GBE increased platelet cAMP levels, suggesting a mechanism involving reduced intracellular calcium (Ca2+).
Conclusions:
- GBE demonstrates potent anti-platelet activity, particularly in whole blood, at low concentrations.
- The anti-platelet effects of GBE are likely mediated through mechanisms involving cAMP and potentially Ca2+ regulation.
- GBE shows promise as an orally administered therapeutic agent for preventing platelet aggregation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...